The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Regeneron Pharmaceuticals (REGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Regeneron Pharmaceuticals is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. REGN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for REGN's full-year earnings has moved 12.79% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, REGN has returned 4.14% so far this year. At the same time, Medical stocks have gained an average of 11.06%. As we can see, Regeneron Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, which includes 280 individual stocks and currently sits at #108 in the Zacks Industry Rank. On average, stocks in this group have gained 1.40% this year, meaning that REGN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to REGN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Regeneron Pharmaceuticals (REGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Regeneron Pharmaceuticals is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. REGN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for REGN's full-year earnings has moved 12.79% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, REGN has returned 4.14% so far this year. At the same time, Medical stocks have gained an average of 11.06%. As we can see, Regeneron Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, which includes 280 individual stocks and currently sits at #108 in the Zacks Industry Rank. On average, stocks in this group have gained 1.40% this year, meaning that REGN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to REGN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on REGN - FREE